Patents Assigned to University of Zurich
  • Patent number: 10544213
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 28, 2020
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Fabrice Heitz, Fabian Wirth, Tobias Welt
  • Publication number: 20200017577
    Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 16, 2020
    Applicants: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
  • Patent number: 10450365
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: October 22, 2019
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic
  • Publication number: 20190263896
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 29, 2019
    Applicant: University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Publication number: 20190233506
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: September 12, 2018
    Publication date: August 1, 2019
    Applicants: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Patent number: 10301381
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: May 28, 2019
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • Publication number: 20190153082
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 23, 2019
    Applicant: University of Zurich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 10259866
    Abstract: Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 16, 2019
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
  • Publication number: 20180371065
    Abstract: Provided are novel human ?-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: January 9, 2018
    Publication date: December 27, 2018
    Applicants: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
  • Publication number: 20180355027
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: March 7, 2018
    Publication date: December 13, 2018
    Applicants: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • Patent number: 10131708
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: November 20, 2018
    Assignee: University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 9975947
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: May 22, 2018
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • Publication number: 20180134773
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 17, 2018
    Applicant: University of Zurich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 9896504
    Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: February 20, 2018
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
  • Publication number: 20180002409
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 8, 2017
    Publication date: January 4, 2018
    Applicants: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Publication number: 20170369592
    Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 28, 2017
    Applicants: Mabimmune Diagostics AG, Neurimmune Holding AG, University of Zurich
    Inventors: Chad BROKOPP, Jan GRIMM, Benoit COMBALUZIER, Mareike GOERANSON, Christine LOHMANN, Simon HOERSTRUP, Roger NITSCH
  • Patent number: 9828420
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 28, 2017
    Assignee: University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 9828638
    Abstract: Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: November 28, 2017
    Assignees: VIB VZW, Universiteit Antwerpen, University of Zurich, Medical University of Graz
    Inventors: Annelies Rotthier, Vincent Timmerman, Michaela Auer-Grumbach, Thorsten Hornemann
  • Publication number: 20170283491
    Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
    Type: Application
    Filed: May 12, 2017
    Publication date: October 5, 2017
    Applicant: University of Zurich
    Inventors: Roger Nitsch, Christoph Hock, Christoph Esslinger, Marlen Knobloch, Kathrin Tissot, Jan Grimm
  • Patent number: 9771413
    Abstract: Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: September 26, 2017
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Roland Martin, Benoit Combaluzier, Ivan Jelcic